CTI Life Sciences invests in $22 mln Series A funding of SutroVax
U.S. biopharmaceutical vaccine startup SutroVax has received US$22 million in a Series A financing. The round was led by U.K. venture capital firm Abingworth and was joined by Canadian firm CTI Life Sciences, Longitude Capital and Roche Venture Fund. Based in San Francisco, the recently-established SutroVax is developing vaccines for infectious disease targets. It said it plans to use the proceeds of the investment to advance multiple vaccines in its pipeline through pre-clinical proof of concept. In January 2015, the Montréal-based CTI Life Sciences raised $134 million in the initial close of its second fund, CTI II, which is targeted to bring in $150 million.
23 July 2015•3 mins read
